Abstract OBJECTIVE: To evaluate the prevalence of sensitivity changes in patients during the cycle of chemotherapy with taxanes and the impacts on quality of life. DESIGN: A prospective, observational, Approved study was conducted at the Oncomastology outpatient clinic of Hospital São Paulo- Unifesp, in the period from November 2018 to February 2022, where 102 women with breast cancer were selected and 79 patients who underwent chemotherapy with paclitaxel were included. METHODS: Collection of demographic and clinical information. Used stesiometer that assessed sensitivity in dermatos and myotomes in the following body regions: arms, hands, legs and feet. FACT/GOG-Ntx Questionnaire analyzed the quality of life and chemotherapy-induced peripheral neuropathy of the patients before starting chemotherapy. All participants were informed and signed an informed consent form. RESULTS: The mean age was 49 years, mean BMI was 27.95Kg/m2, NICC (Invasive Carcinoma not special) represented 89.9% of the sample, 88.6% had Neoadjuvant Chemotherapy, regarding the size of the tumor 45.6% presented from 2 to 5 cm, of the pre existing diseases Diabetes mellitus 15.2% and Systemic Arterial Hypertension 30.4%. The initial moment in relation to sensitivity alterations, of the arm regions presented (right C6 (HC 1.05-1.23) left C6 (HC 1.05- 1.23), and legs (right L5 (HC 1.14 -1.55) left L5 (HC1.22 - 1.52) and right S1 (HC 1.21-1.47) left S1 (HC 1.21-1.48). The conversion of the Estesiometer colors into numbers followed as follows, Green (1.0): normal sensitivity, Blue (2.0): decreased sensitivity. The FACT/Taxane (TOI) quality of life Questionnaire (30 items) its scores 0-120,(average 91.44 points) demonstrates in its response impairment in more than 80 % in the quality of life in the domains. Physical Well-Being-PWB (0-28 points) (mean 20.28/HC 18.88-21.66), Functional Well-Being-FWB (0-28 points) (mean16.00/HC14.22-17.22) and in the specific questions about chemotherapy-induced peripheral neuropathy (CPIN), TaxS (0-64 points) (mean 55.16/HC 52.74-57.26) reduced scores. CONCLUSION: It is concluded that mean age, overweight, tumors between 02 and 05 cm were the most prevalent among patients diagnosed with breast cancer. At the beginning of chemotherapy containing paclitaxel, sensitivity changes were not present characterizing arthralgia, myalgia and the hand-foot syndrome (CPIN). The quality of life evaluated by FACIT/Taxane, showed a reduction of 80% in the scores of the domains Physical Well-Being-PWB, Functional Well-Being-FWB and general quality of life, that is, the quality of life of patients from the time of diagnosis is already very compromised. Key words: Breast neoplasm, adjuvant drug treatment, chemotherapy, quality of life. Number of Opinion: 2.351.174 DATA OF THE OPINION, CEP Number: 0934/2017 of the ethics in research committee. Registered in Clinical Trials on 12/12/2017, protocol number -NCT 03373032. Table 1: Results of the sensitivity of dermatos and myths (monofilaments) undergoing chemotherapy cycles with paclitaxel (eyes closed) Legend: Analysis of quantitative frequencies, Mean, Standard Deviation and Confidence Interval, Percentage (%) and Absolute number. Citation Format: Roberta P. Costa Luz, Carmen S. Alliz, Samantha K. Lopes de Almeida Rizzi, Cinira Haddad, Christiano Bittencourt Machado, Afonso Nazário, Gil Facina. Prospective observational study of breast cancer patients during the cycle of chemotherapy with taxanes: evaluation of the incidence and prevalence of peripheral neuropathy [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P4-03-41.